Enhanced delivery of a low dose of aducanumab via FUS in 5×FAD mice, an AD model

BACKGROUND: Aducanumab (Adu), which is a human IgG1 monoclonal antibody that targets oligomer and fibril forms of beta-amyloid, has been reported to reduce amyloid pathology and improve impaired cognition after administration of a high dose (10 mg/kg) of the drug in Alzheimer’s disease (AD) clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Chanho, Yang, Eun-Jeong, Shin, Jaewoo, Park, Junwon, Kim, Si-Hyun, Park, Seong-Wook, Chang, Won Seok, Lee, Chang-Han, Kim, Hyunju, Kim, Hye-Sun, Chang, Jin Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793531/
https://www.ncbi.nlm.nih.gov/pubmed/36575534
http://dx.doi.org/10.1186/s40035-022-00333-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793531/
https://www.ncbi.nlm.nih.gov/pubmed/36575534
http://dx.doi.org/10.1186/s40035-022-00333-x

Ejemplares similares